A comprehensive view of Seagen Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
Pfizer halts construction of Seagen's US$350.0M manufacturing site in Everett, Washington, after US$43.0B buyout; Pfizer plans to produce Seagen's commercial products at its Sanford, North Carolina, facility and repurpose existing Seagen employees
Published:
March 04, 2024
by FiercePharma
|
Pfizer unveils new business unit for cancer research following poor financial year and US$43.0B buyout of oncology-focused firm Seagen; Pfizer anticipates the pipeline could generate over eight blockbuster medicines by 2030
Published:
March 01, 2024
by BioPharma Dive
|
Daiichi Sankyo secures a win in ongoing patent litigation with Seagen after the U.S. Patent and Trademark Office invalidates all claims to the 039 patent; Seagen plans to appeal the decision
Published:
January 18, 2024
by FiercePharma
|
Pfizer completes acquisition of oncology biotech firm Seagen for US$43.0B, doubling the company's oncology programs; to address FTC concerns, Pfizer to donate the rights of royalties from US Bavencio sales to the American Assn. for Cancer Research
Published:
December 14, 2023
by Pfizer Inc.
|
Pfizer receives all necessary approvals for Seagen acquisition, set to close deal on December 14; Pfizer also creates Pfizer Oncology Division that will integrate certain oncology commercial and R&D operations from both companies
Published:
December 12, 2023
by Pfizer Inc.
|
Ask us about our R&D/Patents market view